WO1999009160A1 - Proteines de regulation de cycle cellulaire - Google Patents
Proteines de regulation de cycle cellulaire Download PDFInfo
- Publication number
- WO1999009160A1 WO1999009160A1 PCT/JP1998/003641 JP9803641W WO9909160A1 WO 1999009160 A1 WO1999009160 A1 WO 1999009160A1 JP 9803641 W JP9803641 W JP 9803641W WO 9909160 A1 WO9909160 A1 WO 9909160A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aim
- protein
- cells
- amino acid
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
Definitions
- the present invention relates to a gene encoding a novel cell cycle regulatory protein AIM-1 (aurora and IPL-1 like midbody-associated protein kinase), a recombinant vector containing the gene, and a transformant using the vector.
- the present invention also involves abnormal cell proliferation including an oligonucleotide or a peptide nucleic acid capable of specifically hybridizing with a nucleotide sequence encoding the AIM-1 protein, an antibody recognizing AIM-1 and an inhibitor against the AIM-1 protein.
- the present invention relates to a therapeutic agent for a disease, and a method for screening a substance having serine-threonine inhibitory activity using the AIM-1 gene or AIM-1 protein.
- Mitosis is the basic form of division of the nucleus of eukaryotic cells, a highly coordinated process by which eukaryotic cells can ensure the accuracy of chromosome segregation.
- the basic number of chromosomes is determined by the species and is often an integral multiple of that number.However, if an error occurs at the mitosis stage, the number of chromosomes increases by one to several from the integral multiple. (Aneuploid), which is thought to lead to cell death and carcinogenesis.
- IPL—1 (Francisco of Drosophia melanogas ter) O au rora (Glover et al, Cell 81: 95-105, 1995) and the most related germinating yeast (Saccharomyces cerevisiae) et al., Mol. Cell. Biol. 14: 4731-40, 1994) is a molecule involved in the M phase of mitosis, and is a molecule required to maintain the accuracy of chromosome segregation. It is considered.
- An object of the present invention is to search for a molecule that regulates the cell cycle in a mammal and determine the nucleotide sequence of a gene that encodes the same.
- genetic recombination using a recombinant vector containing the sequence It is to show the possibility of developing a new drug by producing such a molecule using technology and constructing a screening system using it. Disclosure of the invention
- the present inventors screened a rat cDNA library using the conserved sequence of the serine threonine kinase domain (FEBS LETT. 320: 246-250, 1993) as a probe to obtain a novel cell cycle regulatory protein kinase AIM. — We isolated the gene encoding 1 (auro ra and IPL-1 1 i ke midbody-as soci ated tein kinase) and succeeded in elucidating its function.
- the present invention relates to a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 2 in the sequence listing, or an amino acid sequence obtained by substituting, deleting or adding a part of the amino acid sequence shown in SEQ ID NO: 2 in the sequence listing. And a DNA comprising a nucleotide sequence encoding a protein having cell cycle regulatory activity or a nucleotide sequence hybridizing thereto.
- the present invention also provides a recombinant vector containing a gene encoding the AIM-1 protein.
- the present invention further provides a prokaryotic or eukaryotic host cell transformed by a recombinant vector comprising a gene encoding the AIM-1 protein.
- the present invention further comprises culturing a transformant obtained by transformation with a recombinant vector containing a gene encoding AIM-1 protein, and isolating and purifying the produced target protein.
- a method for producing AIM-1 protein is provided.
- the present invention further provides a recombinant AIM-1 protein produced by the above production method.
- the present invention further provides a method for specifically hybridizing a gene encoding AIM-1 protein.
- the present invention further provides an antibody that recognizes a peptide having at least 5 consecutive amino acids in the amino acid sequence shown in SEQ ID NO: 2 in the sequence listing.
- the present invention further provides a therapeutic agent for a disease associated with abnormal cell proliferation, which comprises an inhibitor for AIM-1 protein.
- the present invention further provides a method for screening a substance having a serine-threonine inhibitory activity using the AI-1 gene or AI-1 protein.
- Figure 1 Comparison of the amino acid sequence of AIM-1 with the amino acid sequence of aurora gene derived from Drosophila and the IPL-1 gene derived from yeast.
- Figure 2 a was isolated from various rat tissues poly (A) + RNA 32 P- labeled AIM-1 c DNA fragment and Haiburidizu to Roh one Zanburotto analysis obtained FIG (electrophoresis (Photo)
- Figure 2b shows the relationship between the expression pattern of AIM-1mRNA and the cell cycle (photograph of electrophoresis).
- Figure 2c shows changes in the mass of AIM-1 protein in NRK-49F cells at each time point in the cell cycle using an antibody against a peptide consisting of the C-terminal 13 amino acids of the AIM-1 sequence. (Photo of electrophoresis).
- Fig. 3 NRK-49F cells were stained with the anti-AIM-1 polyclonal antibody prepared in Example 5 (left palm of Fig. 3) and anti- ⁇ -tubulin monoclonal antibody (center ⁇ in Fig. 3). It is a figure (photograph showing the morphology of an organism) obtained by DNA staining using Hoechst 33258 (right in Fig. 3).
- a is the interphase (inte ⁇ hase)
- b is the early phase (prophase)
- c is the middle phase (metaphase)
- d is the late late phase (late an aphase)
- e is the final phase (telophase)
- f Indicates cytokinesis.
- 3g shows the results of transfection of mink lung epithelial (Mvl Lu) cells with pUHD10-3 / FLAG-AIM-1 (WT) prepared in Example 7 for 24 hours in doxycycline-free medium. And during culturing, then anti-FLAG monoclonal antibody M 2 (KODAK) (left column), in which stained similarly with Usagi anti 7 one-tubulin antibody (middle column) and Hoechst33258 (right column).
- KDAK anti-FLAG monoclonal antibody M 2
- Figure 4A shows the induction of wild-type FLAG-AIM-1 (WT) or inactivated FLAG-AIM-1 (K-R) in Mv 1 Lu cells and removal of doxycycline (D0X) After incubation, the cells were cultured for 18 hours, the obtained cells were collected, and the cell lysate was subjected to immunoblotting analysis using an anti-FLAG monoclonal antibody (photograph of electrophoresis).
- WT wild-type FLAG-AIM-1
- K-R inactivated FLAG-AIM-1
- D0X doxycycline
- FIG. 4B shows the non-synchronous vector transformed with vector-only (a, d), FLAG-AIM-1 (WT) (b, e), or FLAG-AIM-1 (K-R) (c, f).
- FIG. 4 is a diagram (photograph showing the form of an organism) in which cells were cultured in the presence (ac) or absence (df) of DOX for 72 hours, and stained with Giemsa solution.
- a, b, c are shown from left to right in the upper column
- d, e, f are shown from left to right in the lower column.
- FIG. 4C shows a cell sample collected, cells fixed with ethanol, stained with propidium iodide, and subjected to FACS analysis.
- Figure 5D shows ⁇ -tubulin obtained by superposing each image of MAG 1 Lu cells expressing FLAG-AIM-1 (K-R) shown in Figure 4B. (Green) and DNA (red) (Providium iodide) double staining (photograph showing biological morphology). After removal of doxycycline, abnormal cells with two (a), four (b), eight (c) or more than 10 nuclei appeared.
- FIG. 5E shows that Mv 1 Lu cells transfected with FLAG-AIM-1 (WT) or FLAG-AIM-1 (KR) were cultured for 2 weeks in the presence or absence of DOX, respectively. It is the figure (photograph showing the form of an organism) stained with Giemsa solution. BEST MODE FOR CARRYING OUT THE INVENTION
- cDNA encoding AIM-1 was obtained as follows.
- the rat cDNA library was subjected to PCR using the ⁇ type. The PCR product was separated by agarose gel electrophoresis to obtain a cDNA fragment, which was identified.
- the rat NRK-49F fibroblast DNA library was screened by polymerase chain reaction (PCR) to isolate the V-V I I subdomain of the serine-sleonine protein kinase.
- PCR polymerase chain reaction
- Three full-length clones were identified by screening 1 ⁇ 10 clones of the same library using the above cDNA fragment (SEQ ID NO: 1) as a probe.
- the sequence of the cDNA of AIM-1 is shown in SEQ ID NO: 2, and the predicted amino acid sequence is shown in SEQ ID NO: 2.
- the amino acid sequence of AIM-1 consists of 344 amino acids and has a molecular weight of 39.2 kD. Eighty amino acid residues of the N-terminal sequence are a serine-threonine type protein kinase catalytic domain having homology to Drosophila aurora and yeast IPL-1 (Hanks et al., Science 241: 42-52). , 1988).
- FIG. 1 shows a comparison of the catalytic domains of the aurora and IPL-1 genes and the AIM-1 gene.
- AIM-1 shows 60% and 46% homology in aurora and IPL-1 and its catalytic domain, respectively, but the amino acid sequence at the N-terminus is not similar.
- rat AIM-1 cDNA fragment of the present invention is prepared from a human tissue that seems to be rich in AIM-1 (eg, a proliferating tissue such as testis, lung, or spleen).
- AIM-1 eg, a proliferating tissue such as testis, lung, or spleen.
- human AIM-1 cDNA can be obtained.
- human cDNA was isolated by screening a cDNA library derived from human intestine and heart by this method.
- Human AIM-1 protein encoded by the human cDNA had 81% amino acid identity with rat AIM-1.
- human AIM-1 protein exhibited the same cell cycle regulatory activity as rat AIM-1 and was suggested to be a homolog of rat AIM-1.
- AIM-1 protein of the present invention When used, AIM-1 protein can be produced in large quantities by genetic recombination technology and used for pharmaceutical purposes.
- prokaryotic or eukaryotic host cells can be transformed by incorporating the gene encoding the AIM-1 protein of the present invention into an appropriate vector.
- the gene can be expressed in each host cell by introducing an appropriate promoter and a sequence related to expression into these vectors.
- an appropriate promoter and a sequence related to expression into these vectors.
- eukaryotic genes are considered to exhibit polymorphism, as is known for the human interferon gene, which may replace one or more amino acids. In some cases, the amino acid does not change at all even if the nucleotide sequence changes.
- a cell lacking or adding one or more amino acids in the amino acid sequence of SEQ ID NO: 2 in the sequence listing, or a polypeptide in which an amino acid is substituted with one or more amino acids is also used as a cell. May have cycle-regulating activity.
- a polypeptide obtained by converting a base sequence corresponding to cysteine of the human interleukin 2 (IL-2) gene to a base sequence corresponding to serine retains IL-12 activity.
- the present invention includes a gene in which the obtained polypeptide has cell cycle regulatory activity and hybridizes with the gene shown in SEQ ID NO: 2.
- the hybridization conditions can be the same as those used in ordinary probe hybridization (for example, Molecular Cloning: A Laboratory Manual, Sambrook et al., Cold Spring Harbor Laboratory Press, 1989). .
- Standard methods include, for example, 6XSS 0.05XBLOTTO (Bovine Lacto Transfer Technique Optimizer) as described in the literature (Molecular Cloning: A Laboratory Manual, Sambrook et al., Cold Spring Harbor Laboratory Press, 1989).
- 6XSS 0.05XBLOTTO Bovine Lacto Transfer Technique Optimizer
- 68 in solution preferably 18 hours at 60-68 in Express Hyb TM Hybridization Solution (Clontech) solution or 18 hours at 60-68 in Rapid-hyb Buffer (Amersham) solution
- a gene that can be hybridized under the following conditions and that is recognized by the probe complementary to the DNA according to claim 1 and that encodes a protein having a biological function of the AIM-1 protein is also included in the present invention. Include.
- the present invention also encompasses genes isolated by these methods and encoding a protein having a biological function of the AI M-1 protein (Molecular Cloning: A Laboratory Mannual, Sambrook et al. , Cold Spring Harbor Laboratory Press, 1989).
- An expression vector can include an origin of replication, a selectable marker, a promoter, an RNA splice site, a polyadenylation signal, and the like.
- Prokaryotic host cells among the hosts used in the expression system include, for example, Escherichia coli and Bacillus subtilis.
- host cells of eukaryotic microorganisms include, for example, yeast and slime mold.
- insect cells such as Sf9 may be used as host cells.
- host cells derived from animal cells include, for example, COS cells, CHO cells, and the like.
- protein produced by culturing the transformant transformed with the gene encoding the AIM-1 protein can be isolated and purified from the inside or outside of the cell.
- the amino acid sequence shown in SEQ ID NO: 2 in the above sequence listing A nucleotide sequence encoding an amino acid sequence obtained by substituting, deleting or adding a part of the amino acid sequence shown in SEQ ID NO: 2 in the Sequence Listing as well as a protein obtained from a gene containing the nucleotide sequence encoding the amino acid sequence
- a protein obtained using a gene containing a base sequence that hybridizes thereto is included in the present invention as long as it has a biological function of AIM-1 protein, that is, a cell cycle regulating activity.
- the AIM-1 protein can be separated and purified by the separation and purification methods used for ordinary proteins. For example, each panicle chromatography, ultrafiltration, salting out, dialysis, etc. can be appropriately selected and used in combination.
- antisense DNA can be prepared based on the nucleotide sequence of the gene encoding the AIM-1 protein.
- Antisense DNA has a complementary nucleotide sequence to mRNA, and forms a base pair with mRNA, thereby interrupting the flow of genetic information and suppressing the synthesis of the final product, AIM-1 protein.
- the antisense DNA that can be used in the present invention is an oligonucleotide that can specifically hybridize with the nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 2 in the sequence listing.
- oligonucleotide refers to oligonucleotides and analogs thereof formed from naturally occurring bases and sugar moieties linked by native phosphodiester bonds.
- first group included by this term is a naturally occurring species or a synthetic species produced from a naturally occurring subunit or a homolog thereof.
- a subunit refers to a combination of base monosaccharides linked to an adjacent subunit by a phosphodiester bond or another bond.
- a second group of oligonucleotides are analogs thereof, which refers to residues having a non-naturally occurring moiety that functions similarly to an oligonucleotide.
- oligonucleotide analogues include modified base forms, However, species containing purines and pyrimidines other than those normally found may be used.
- the oligonucleotide according to the invention preferably has 5 to 40, more preferably 8 to 30, and more preferably 12 to 30 units.
- the target portion of the mRNA to which the oligonucleotide hybridizes is preferably a transcription initiation site, a translation initiation site, an intron / exon binding site or a 5'cap site, but steric hindrance is considered in consideration of the secondary structure of the mRNA.
- a site without a marker should be selected.
- a peptide nucleic acid (see, for example, Bioconjugate Chem. Vol. 5, No. 1, 1994) can be used instead of the oligonucleotide.
- a particularly preferred embodiment of the present invention is an oligonucleotide or a peptide nucleic acid that hybridizes with the nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 2 in the sequence listing and can inhibit the expression of the AIM-1 protein.
- the oligonucleotide according to the present invention can be produced by a synthesis method known in the art, for example, a solid phase synthesis method using a synthesizer such as Applied Biosystems. Similar methods can be used to produce other oligonucleotide analogs, such as phosphorothioalkylated derivatives (Murakami Akira et al., “Chemical Synthesis of Functional Antisense DNA”, Organic Synthetic Chemistry). 48 (3): 180-193, 1990).
- an oligonucleotide or a peptide nucleic acid capable of specifically hybridizing with the gene encoding AIM-1 of the present invention to an animal can suppress the production of AIM-1 protein in the animal.
- -1 has a function necessary for the progression of the M phase of cell division, as described in detail below, so that the oligonucleotide or the peptide nucleic acid of the present invention is administered to cancer cells by administering them to the cancer cells. Can be suppressed or stopped.
- the oligonucleotide of the present invention is expected to be effective not only for treating cancer cells but also for other proliferative diseases.
- an antibody that recognizes a peptide having at least 5 consecutive amino acids in the amino acid sequence shown in SEQ ID NO: 2 of the sequence listing of the present invention
- a conventional method for example, Shinsei Chemistry Laboratory Course 1, Protein I, P. 389—397, 1992
- Antibodies include polyclonal and monoclonal antibodies, and methods for making them are also known to those skilled in the art.
- the anti-AIM-1 antibody obtained in this manner can be used for various immunoassays such as enzyme immunoassays such as ELISA, radioimmunoassay, immunofluorescence, or AIM-1 protein. It can be used for column purification.
- enzyme immunoassays such as ELISA, radioimmunoassay, immunofluorescence, or AIM-1 protein. It can be used for column purification.
- an inhibitor for AIM-1 for example, an agonist or an antibody such as AIM-1 (K—R) or an inhibitor of protein phosphorylation activity, or an antisense strand
- AIM-1 an agonist or an antibody such as AIM-1 (K—R) or an inhibitor of protein phosphorylation activity, or an antisense strand
- a gene encoding the AIM-1 (KR) protein produced by the present invention is site-specifically administered to a cancer cell and expressed at the cancer cell site to suppress or stop the growth of the cancer cell. Treatment can also be expected.
- a method for screening a substance having serine-threonine kinase inhibitory activity using the AIM-1 gene or AIM-1 protein can be performed.
- a reaction solution containing ATP e.g., myosin light chain, histone protein, synthetic substrate
- AIM-1 protein and inhibitor candidate substance Oh Rui mixed solvent for example, 30 ° C
- AIM-1 gene was tested by Northern blot analysis ( Figure 2a).
- Poly (A) + RNA isolated from various rat tissues was hybridized with a 32 P-labeled AIM-1 cDNA fragment. A band of about 2. O kb of AIM-1 was detected in all tissues tested, but particularly in testis, spleen and lung.
- AIM-1 protein In order to study the function of the AIM-1 protein, a peptide consisting of the C-terminal 13 amino acids of the AIM-1 sequence was synthesized, and an antibody against this peptide was prepared. Using this antibody, changes in the amount of AIM-1 protein in NRK-49F cells at each time point in the cell cycle were analyzed (FIG. 2c). As a result, the AIM-1 protein, detected as a band of about 40 Kd, begins to accumulate at the borderline phase of S / G2, reaches the highest level in M phase, and decreases dramatically in the next G1 phase That was shown. Similar results were obtained using cells that had their cell cycle synchronized by the double thymidine block and release method. These data are consistent with the Northern blot analysis.
- AIM-1 protein is best expressed during the M phase of cell division.
- the C-terminus of AIM-1 contains the putative consensus sequence of the destructionbox recognized by the proteosome (Fig. 1), so the AIM-1 protein is eye 1 in B (Glotzer et al., Nature 349: 132-138, 1991) and ubiquitin proteasome-dependent proteolysis, like other G2-M regulatory proteins such as cut 2 (Funabiki et al., Nature 381: 438-441, 1996) Maybe.
- Mv 1 Lu cells transfected with wild-type FLAG-AIM-1 (WT) or FLAG-AIM-1 (KR), which are Mv 1 Lu cells having only one vector, are transformed into doxycycline (a tetracycline analog) After 24 hours of growth in the presence or absence of E. coli, they were subjected to Western blot using an anti-FLAG antibody (FIG. 4A).
- FLAG—AI M-1 (KR) was induced for 72 hours, about 68% of the cells failed to undergo normal cytokinesis and had two or more nuclei (Fig. 4 ⁇ , Table 1). Furthermore, these cells were much larger in size than normal cells ( Figure 4Bf, Figure 5D).
- AIM-l (WT) and AIM-1 (K-IR) plasmids were transiently expressed in NRK-49 F cells and human diploid fibroblast KD cells.
- the effect was compared with that obtained by transformation using only a vector.
- These constructs were transformed into cells with the reporter construct RSV- / 3-galactosidase to prepare ⁇ -galactosidase expression plasmids for use as positive internal controls for transformation (Table 1). ). Transformation with the vector alone did not affect normal cell cycle progression, but transformation with the AIM-l ( ⁇ -R) construct resulted in many cells with more than one nucleus. (NRK-49F cells: 62%, KD cells: 38%).
- the nuclei of these AIM-1 (K—R) expressing cells divide three to four times in 4 to 5 days to have more than 10 nuclei per cell (Fig. 5D). It will not attach to the plate without further splitting.
- AIM-1 (KR) on the reproductive potential, the cells were cultured in the presence or absence of doxycycline for 2 weeks (Fig. 5E). Inhibition of division was observed in Lu cells, but not in cells expressing AIM-l (WT).
- KLP kinesin-like protein
- cell extracts were prepared by the following method.
- sequences of the oligonucleotide primers 1 and DFGVSGQ (sense primers for the conserved sequence MHRDVKP (SEQ ID NO: 3) of the serine threonine kinase domain are as follows.
- Rat DNA library (FEBS LETT. 320: 246-250, 1993) was made into a gun type, and the above primers 1 and 2 were used as primers, and then with vent DNA polymerase (94 ° C: 1 minute). , 55 ° C: 1 minute, 72 ° C: 2 minutes) for 40 cycles of PCR. The obtained PCR product was separated by agarose gel electrophoresis to obtain a fragment.
- NRK-49F RNA in the logarithmic growth phase was obtained by the guanidine method, and the mRNA was purified on an Oligot d T cellulose column. Oligo d TZNot 1 was used as a primer, cDNA was converted with reverse transcriptase, EcoRI adapter was ligated, and cDNA was inserted into expression vector pcTerralll (FEBS LETT. 320: 246-250, 1993). .
- the sequence of the cDNA fragment (SEQ ID NO: 1) obtained in Example 1 was used as a probe for gene screening.
- the probe was labeled with 32 P, hybridized with the NRK-49 Fc DNA library bound to the filter under the following conditions, and a positive clone was isolated.
- Hybridization solution 6x SSPE, 0.5% SDS, 10x Den hardt so lOOu / ml denatured dicine sperm DNA.
- the filter was washed under the following conditions: (2x SSC, 0.1, SDS for 15 minutes, 0.2x SSC, 0.1% SDS for 15 minutes).
- SEQ ID NO: 2 shows the cDNA sequence of AIM-1 and the amino acid sequence predicted therefrom.
- FIG. 1 shows a comparison of the amino acid sequence of AIM-1 with the amino acid sequences of the aur0ra gene derived from Drosophila and the IPL-1 gene derived from yeast. In the figure, the amino acid numbers are shown on the left. The number above the amino acid sequence indicates the kinase subdomain described in Hanks et al. (Science 241: 42-52, 1988). The same amino acids conserved in two or more sequences are shown in black.
- V I I from the A I M-1 subdomain V lb indicates the sequence first identified by PCR.
- the asterisks are the portions used in the preparation of the anti-peptide antibody N12 described in the examples below.
- the short underlined portion of the amino acid sequence at the C-terminus of AIM-1 is a putative proteolytic box site.
- Example 3 Expression of AIM-1 gene in rat tissue
- Confluent rat NRK-49F cells were placed in serum-free medium for 2 days and then inoculated in serum-containing DMEM medium at a ratio of 1: 3 to allow the cell cycle to progress synchronously.
- 2 g of poly (A) + RNA was added.
- a G3PDH gene probe (Nippon Gene) was used. The results obtained are shown at the top of Figure 2b.
- FACS analysis Becton Dickinson
- the FACS can Becton Dickinson
- the peptide with the asterisk (from V to C-terminal) in the amino acid sequence of AIM-1 shown in Fig. 1 was synthesized, and this was used as KLH. (Keyhole limpet to mocchanin) and injected into a egret.
- Serum was obtained from ⁇ heron, from which it was affinity purified using peptide-immobilized FMP activated cellulose column (Seikagaku) to obtain a polyclonal antibody.
- Example 6 Relationship between AIM-1 protein expression and cell cycle
- the cell cycle proceeded synchronously as in Example 4 above.
- the insoluble protein corresponding to 2 x 10 5 cells was removed and the anti-AIM prepared in Example 5 was removed.
- the antibody was subjected to Western blot analysis using one antibody (N12) as a probe.
- the in vivo transcription / translation product of AIM-1 was used as a control.
- the coding sequence of the full-length AIM-1 cDNA obtained in Example 2 was converted to pUHD 10-3 (Hermann Bujard, Zent rum fur Molekulare Biologi e der Universi tat Heidelberg, Im Neuenheimer Feld 282, W-6900, Heidelberg, Sub-cloning into a plasmid containing the EF1a promoter (Mizushima et al., Nucleic Acids Res. 18: 5322-5326, 1990); FLAG-AIM-1 (WT) labeled with FLAG protein at the end was prepared.
- FLAG-AIM-1 (K-R) was prepared by two-step PCR using the following primers.
- Primer 3 5'-AGA GAA TTC ATG GAC TAC AAG GAC GAT GAC GAC AAG ATG GCT CAG AAA GAG AAC-3 '(SEQ ID NO: 7)
- Primer 4 5'-CTT GAA GAG GAT CCT TAG CGC CAC GAT-3 '(SEQ ID NO: 8)
- Primer 5 5'-ATC GTG GCG CTA AGG ATC CTC TTC AAG-3' (SEQ ID NO: 9)
- Primer 6 5'-GA CTC AGA CTA AAG GGC AGA GGG AGG CAG ACG GCG CGC-3 '(SEQ ID NO: 10)
- Equal amounts of the above fragments (A) and (B) are mixed and PCR is performed using the combination of primer 13 and primer 6.
- the 1.03 kb fragment is purified and the EcoR I and Xbal sites are used. It was cut and inserted into pUHD10-13 multicloning site.
- the FLAG-AIM-1 (WT) prepared in (1) and the FLAG-AIM-1 (K-R) prepared in (2) were expressed. They were then co-transformed into Mv1 Lu cells (ATTC CRL-6584) with the pEFZhygl hygromycin resistance plasmid using the lipofectin method according to the manufacturer's protocol (GIBC0, BRL). Clones were selected in hygromycin (Calbiochem) 0.2 mg / ml and deoxycycline (Sigma). Clones that induced FLAG-AIM-1 (WT) or (K-R) after 18 hours in the absence of deoxycycline were selected by Western blot using an anti-FLAG antibody (M2) as a probe. A clone with an empty vector was used as a control.
- Example 8 Involvement of AIM-1 protein in mitosis
- NRK-49F cells were stained with the anti-AIM-1 polyclonal antibody prepared in Example 5 (left column in FIG. 3) and the anti- ⁇ -tubulin monoclonal antibody (middle in FIG. 3), and the dye Hoechst 33258 was added. DNA staining (right column in Fig. 3).
- a in Fig. 3 indicates the interphase
- b indicates the early phase (prop hase)
- c indicates the metaphase (metaphase)
- d indicates the late anaphase
- e indicates the end.
- F indicates cytokinesis.
- AIM-1 is not detected in metaphase, but is detected later in the center of the spindle. This staining was observed to increase in the midbody (midbody) with the progression of anaphase and cytokinesis.
- the mink lung epithelial (MvI Lu) cells having pUHD 10-3 / FL AG—AI M_1 (WT) prepared in Example 7 were cultured in doxycycline-free medium for 24 hours, and then the anti-FLAG monoclonal antibody M 2 (KODAK) and Egret anti-tubulin antibody (Masuda et al., J. Cell Sci. 109: 165-177, 1996) and stained with Hoechst 33258 in the same manner.
- KDAK anti-FLAG monoclonal antibody M 2
- Egret anti-tubulin antibody Mosuda et al., J. Cell Sci. 109: 165-177, 1996) and stained with Hoechst 33258 in the same manner.
- Wild-type FLAG-AIM-1 (WT) or kinase-inactivated FLAG-AIM-1 (KR) (dominant negative type) prepared in Example 7 was induced in Mv1 Lu cells. After removing doxycycline (DOX), the cells are cultured for 18 hours. Nourished. Cells were harvested and cell lysates were subjected to Immunobut analysis using anti-FLAG monoclonal antibody. The results obtained are shown in FIG. 4A.
- MvI Lu cells were performed under the conditions described in (1) B above.
- Table 1 shows the obtained results.
- the numbers in the table mean the percentage of cells having two or more nuclei for 3-galactosidase positive cells for NRK-49 F cells or KD cells, and two or more nuclei for all cells for MV 1 Lu cells. Means% of cells having More than 160 cells were tested for each cell line.
- Example 10 Isolation of human cDNA, expression of AIM-1 protein and its activity (1) Isolation of human AIM-1 cDNA
- Primer 8 5 '-(A / G) TG (A / T / C / G) AC (A / T / C / G) GACCA (A / T / C / G) CC (A / G) AA (A / G) T-3 '(SEQ ID NO: 12)
- the human DNA (intestinal and heart) -derived cDNA library prepared by the "lone linker” method (Abe, Mamm. Genome 2: 252-259, 1992) was converted into a rust type and Amplified with ExTaq DNA polymerase (Takara, Tokyo) using —7 and 8 as primers.
- the resulting PCR product was subcloned to obtain about 50 fragments for each library and sequenced.
- an oligonucleotide primer 9 for sense against NLLLGLKGELK I SEQ ID NO: 13
- an adapter (dT) -containing adapter for construction of a “lone linker” prepared cDNA library.
- a universal adapter primer 10 for the image was prepared.
- Primer 9 5'-AATCTGCTCTTAGGGCTCAAGGGAGAGCTGAAGATT-3 '(SEQ ID NO: 14)
- Primer 10 5'-TCCACTAATATCGGCCACGCGTCGACTAGTAC-3' (SEQ ID NO: 15)
- a HeLa cDNA library-1 (Otsu et al., FEBS Lett. 320: 246-250, 1993) was screened to isolate a clone containing full-length human AIM-1c DNA. And sequenced.
- AIM-1 expression was tested using colcemid-treated cells. — The accumulation of 1 was observed to be maximal.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/485,534 US6759212B1 (en) | 1997-08-15 | 1998-08-17 | Cell cycle-regulating proteins |
DE69836220T DE69836220T2 (de) | 1997-08-15 | 1998-08-17 | Den zellzyklus regulierende proteine |
EP98937837A EP1004667B1 (en) | 1997-08-15 | 1998-08-17 | Cell cycle-regulating proteins |
AU86496/98A AU8649698A (en) | 1997-08-15 | 1998-08-17 | Cell cycle-regulating proteins |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP23537197 | 1997-08-15 | ||
JP9/235371 | 1997-08-15 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/485,534 A-371-Of-International US6759212B1 (en) | 1997-08-15 | 1998-08-17 | Cell cycle-regulating proteins |
US10/429,849 Division US20040029157A1 (en) | 1997-08-15 | 2003-05-06 | Cell cycle control protein |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999009160A1 true WO1999009160A1 (fr) | 1999-02-25 |
Family
ID=16985104
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/003641 WO1999009160A1 (fr) | 1997-08-15 | 1998-08-17 | Proteines de regulation de cycle cellulaire |
Country Status (6)
Country | Link |
---|---|
US (2) | US6759212B1 (ja) |
EP (1) | EP1004667B1 (ja) |
AT (1) | ATE342971T1 (ja) |
AU (1) | AU8649698A (ja) |
DE (1) | DE69836220T2 (ja) |
WO (1) | WO1999009160A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001030833A1 (fr) * | 1999-10-22 | 2001-05-03 | Shanghai Bio Road Gene Development Ltd. | Nouveau polypeptide, proteine de regulation d'un nouveau cycle cellulaire 53, et polynucleotide codant pour ce polypeptide |
DE10011530A1 (de) * | 2000-03-13 | 2001-09-27 | Robert Elez | Hochwirksame Antisense-Oligodesoxynucleotide gegen Polio-like Kinasel |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004209984B2 (en) | 2003-01-31 | 2010-08-05 | Albor Biologics, Inc. | Immune regulation based on the targeting of early activation molecules |
EP1694686A1 (en) * | 2003-12-19 | 2006-08-30 | Takeda San Diego, Inc. | Kinase inhibitors |
EP1763524A1 (en) * | 2004-04-23 | 2007-03-21 | Takeda San Diego, Inc. | Indole derivatives and use thereof as kinase inhibitors |
US7375212B2 (en) * | 2004-05-24 | 2008-05-20 | Isis Pharmaceuticals, Inc. | Modulation of Aurora B expression |
JP2008510734A (ja) * | 2004-08-18 | 2008-04-10 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
EP1812439B2 (en) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
WO2006060737A2 (en) * | 2004-12-03 | 2006-06-08 | Takeda San Diego, Inc. | Mitotic kinesin inhibitors |
US7682799B2 (en) * | 2005-10-06 | 2010-03-23 | University Of Massachusetts | Cell division marker |
US8119655B2 (en) * | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US20100120717A1 (en) | 2006-10-09 | 2010-05-13 | Brown Jason W | Kinase inhibitors |
EP2223925A1 (en) * | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997022702A1 (en) * | 1995-12-18 | 1997-06-26 | Sugen, Inc. | Diagnosis and treatment of aur-1 and/or aur-2 related disorders |
-
1998
- 1998-08-17 WO PCT/JP1998/003641 patent/WO1999009160A1/ja active IP Right Grant
- 1998-08-17 US US09/485,534 patent/US6759212B1/en not_active Expired - Fee Related
- 1998-08-17 EP EP98937837A patent/EP1004667B1/en not_active Expired - Lifetime
- 1998-08-17 AT AT98937837T patent/ATE342971T1/de not_active IP Right Cessation
- 1998-08-17 AU AU86496/98A patent/AU8649698A/en not_active Abandoned
- 1998-08-17 DE DE69836220T patent/DE69836220T2/de not_active Expired - Fee Related
-
2003
- 2003-05-06 US US10/429,849 patent/US20040029157A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997022702A1 (en) * | 1995-12-18 | 1997-06-26 | Sugen, Inc. | Diagnosis and treatment of aur-1 and/or aur-2 related disorders |
Non-Patent Citations (6)
Title |
---|
FRANCISCO L, WANG W, CHAN C S M: "TYPE 1 PROTEIN PHOSPHATASE ACTS IN OPPOSITION TO IPL1 PROTEIN KINASE IN REGULATING YEAST CHROMOSOME SEGREGATION", MOLECULAR AND CELLULAR BIOLOGY., AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON., US, vol. 14, no. 07, 1 July 1994 (1994-07-01), US, pages 4731 - 4740, XP002917805, ISSN: 0270-7306 * |
KIMURA M, ET AL.: "CELL CYCLE-DEPENDENT EXPRESSION AND SPINDLE POLE LOCALIZATION OF A NOVEL HUMAN PROTEIN KINASE, AIK, RELATED TO AURORA OF DROSOPHILA AND YEAST IPL1", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 272, no. 21, 1 January 1997 (1997-01-01), US, pages 13766 - 13771, XP002917806, ISSN: 0021-9258, DOI: 10.1074/jbc.272.21.13766 * |
KIMURA M, ET AL.: "ISOLATION AND CHARACTERIZATION OF A CDNA ENCODING A HUMAN NOVEL SERINE/THREONINE KINASE, AIK", MOLECULAR BIOLOGY OF THE CELL, AMERICAN SOCIETY FOR CELL BIOLOGY, US, vol. 07, 1 January 1996 (1996-01-01), US, pages 562A, XP002917803, ISSN: 1059-1524 * |
NIWA H, ET AL.: "CELL-CYCLE-DEPENDENT EXPRESSION OF THE STK-1 GENE ENCODING A NOVEL MURINE PUTATIVE PROTEIN KINASE", GENE., ELSEVIER, AMSTERDAM., NL, vol. 169, 1 January 1996 (1996-01-01), NL, pages 197 - 201, XP002917802, ISSN: 0378-1119, DOI: 10.1016/0378-1119(95)00809-8 * |
QIAN N, ET AL.: "THE IPL GENE ON CHROMOSOME 11P15.5 IS IMPRINTED IN HUMANS AND MICE AND IS SIMILAR TO TDAG51, IMPLICATED IN FAS EXPRESSION AND APOPTOSIS", HUMAN MOLECULAR GENETICS, OXFORD UNIVERSITY PRESS, GB, vol. 06, no. 12, 1 January 1997 (1997-01-01), gb, pages 2021 - 2029, XP002917807, ISSN: 0964-6906, DOI: 10.1093/hmg/6.12.2021 * |
SEN S, ZHOU H, WHITE R A: "A PUTATIVE SERINE/THREONINE KINASE ENCODING GENE BTAK ON CHROMOSOME20Q13 IS AMPLIFIED AND OVEREXPRESSED IN HUMAN BREAST CANCER CELL LINES", ONCOGENE, NATURE PUBLISHING GROUP, GB, vol. 14, 1 January 1997 (1997-01-01), GB, pages 2195 - 2200, XP002917804, ISSN: 0950-9232, DOI: 10.1038/sj.onc.1201065 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001030833A1 (fr) * | 1999-10-22 | 2001-05-03 | Shanghai Bio Road Gene Development Ltd. | Nouveau polypeptide, proteine de regulation d'un nouveau cycle cellulaire 53, et polynucleotide codant pour ce polypeptide |
DE10011530A1 (de) * | 2000-03-13 | 2001-09-27 | Robert Elez | Hochwirksame Antisense-Oligodesoxynucleotide gegen Polio-like Kinasel |
Also Published As
Publication number | Publication date |
---|---|
AU8649698A (en) | 1999-03-08 |
EP1004667A1 (en) | 2000-05-31 |
US6759212B1 (en) | 2004-07-06 |
EP1004667B1 (en) | 2006-10-18 |
EP1004667A4 (en) | 2001-04-25 |
DE69836220T2 (de) | 2007-08-30 |
US20040029157A1 (en) | 2004-02-12 |
ATE342971T1 (de) | 2006-11-15 |
DE69836220D1 (de) | 2006-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lee et al. | Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. | |
Toyoshima et al. | p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21 | |
KR100959199B1 (ko) | 신규한 피53 타겟 유전자 에스아이에스피-1 및 그의 용도 | |
Bunz et al. | cDNAs encoding the large subunit of human replication factor C. | |
Pfeifer et al. | The SOX8 gene is located within 700 kb of the tip of chromosome 16p and is deleted in a patient with ATR-16 syndrome | |
Olson et al. | Distinct roles for DH and PH domains in the Lbc oncogene | |
US20070072230A1 (en) | Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene | |
WO1999009160A1 (fr) | Proteines de regulation de cycle cellulaire | |
Seong et al. | Phosphorylation of a novel zinc-finger-like protein, ZPR9, by murine protein serine/threonine kinase 38 (MPK38) | |
JPH10504446A (ja) | Fas会合タンパク質 | |
US7396920B2 (en) | Tumour suppressor and uses thereof | |
AU2001263952A1 (en) | Tumour suppressor and uses thereof | |
US5948643A (en) | Modulators of BRCA1 activity | |
US5925566A (en) | Non-activated receptor complex proteins and uses thereof | |
US6797501B2 (en) | Protein tyrosine phosphatase PTP20 and related products and methods | |
BG64990B1 (bg) | Модулатори на функцията на рецептори от tnf/ngf рецепторното семейство и други протеини | |
EP1125947B1 (en) | Human H37 protein and cDNA encoding the same | |
US5837819A (en) | TAB1 protein | |
EP0803571B1 (en) | TAB1 protein and DNA coding therefor | |
JPH11164694A (ja) | 細胞周期調節タンパク質 | |
EP2007364A1 (en) | Transcription factor modulator | |
AU3829397A (en) | Modulators of BRAC1 activity | |
JP4283531B2 (ja) | マスト細胞の細胞死誘発剤 | |
JP2000262287A (ja) | 炎症関連新規シグナル伝達ポリペプチド | |
JP2002078493A (ja) | 細胞増殖及び遺伝子発現制御に関わる新規遺伝子とその蛋白質 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09485534 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998937837 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998937837 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998937837 Country of ref document: EP |